The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting the growth of the market.
By product and service, the consumables segment accounted for the largest share of the cell-based assays market The cell-based assays market is categorized into major three product and service categories, consuambles, instrumenet & software and services.Consumables dominated the market in 2019.
The large share of this segment can be attributed to the extensive use and repeated purchase of consumables by pharmaceutical and biopharmaceutical companies and the rising number of preliminary studies for the development of therapeutics.
Asia Pacific: The fastest-growing region in the cell-based assays market.
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the government initiatives to increase funding in biopharmaceuticals, growing R&D spending, and partnerships for life science research.
North America: the largest share of the cell-based assays market North America accounted for the largest share of the cell-based assays market. Factors such as the to the availability of government and private funding for life science research, the growing penetration of CROs, comprehensive drug development regulations, and the rapid adoption of advanced technologies in the region are the major factors driving the market growth.
Breakdown of primaries The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: • By Respondent– Supply Side- 70%, Demand Side- 30% • By Designation— Executives- 25%, CXOs, Directors- 20%, Managers - 55% • By Region— North America - 50%, Europe - 20%, APAC – 20%, LATAM- 5%, MEA- 5%
The cell-based assays market is dominated by a few globally established players such as Becton, Dickinson and Company (US), Cell Signaling Technology, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Promega Corporation (US), Charles River Laboratories (US), Lonza (Switzerland), BioAgilytix Labs (US), Reaction Biology Corporation (US), AAT Bioquest (US), IBR Inc. (Switzerland), PBL Assay Science (US), Eurofins (US), InvivoGen (US), TopoGEN, Inc. (US), Ca3 Bioscience (Neuromics) (US), Cell Biolabs, Inc. (US), Carna Biosciences, Inc. (Japan), Dojindo Molecular Technologies, Inc. (US), Enzo Life Sciences, Inc. (US), BPS Bioscience, Inc. (US), SGS SA (Switzerland), and MLM Medical Laboratories (MD Biosciences) (US).
Research Coverage: The report segments the cell-based assays market based on region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), Consumables (Reagents, Assay Kits (Reporter Gene Assays, Second Messenger Assays, Cell Growth Assays, Cell Death Assays, Other Assay Kits), Cell Lines (Immortalized Cell Lines, Primary Cell Lines, Stem Cell Lines), Microplates, Probes & Labels, Other Consumables), Instruments & Software, Services, Application (Drug Discovery (Pharmacodynamic Studies, Pharmacokinetic Studies, Toxicity Studies), Basic Research and Other Application), End users (Pharmaceutical & Biopharmaceutical Companies, CROs, and Academic & Research Institutes).
The report also provides a comprehensive review of market drivers, challenges, and opportunities in the cell-based assays market
Key Benefits of Buying the Report: The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the cell-based assays market and provides them information on key market drivers, challenges, and opportunities
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Apr 2021
Major players in the clinical oncology next generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences. The global clinical oncology next generation sequencing...
359 pages •
By Global Industry Analysts
• Apr 2021
- A Lesson Taught by the Pandemic is the Need to Have Better Health Systems & More Effective Drugs. GPCRs to Reach $3.8 Billion On the Back of Increased Drug R&D Spending
- The global market for G-Protein Coupled Receptors (GPCRs) is projected to reach US$3.8 billion by the year 2027, trailing a post COVID-19...
Chemotherapy Induced Nausea and Vomiting (Other Diseases) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Drugs in Development, 2021, provides an overview of the Chemotherapy Induced Nausea and Vomiting...
Toll Like Receptor 3 (CD283 or TLR3) - Drugs in Development, 2021 Summary Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll...
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 18.104.22.168) - Drugs in Development, 2021 Summary Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 22.214.171.124) - Drugs in Development,...
Forkhead Box Protein M1 (Hepatocyte Nuclear Factor 3 Forkhead Homolog 11 or M Phase Phosphoprotein 2 or MPM 2 Reactive Phosphoprotein 2 or Transcription Factor Trident or Forkhead Related Protein FKHL16 or Winged Helix Factor From INS 1 Cells or FOXM1) - Drugs in Development, 2021 Summary Forkhead...
Interferon Beta (Fibroblast Interferon or IFNB or IFNB1) - Drugs in Development, 2021 Summary Interferon Beta (Fibroblast Interferon or IFNB or IFNB1) - Drugs in Development, 2021 provides in depth analysis on Interferon Beta (Fibroblast Interferon or IFNB or IFNB1) targeted pipeline therapeutics....
Cells Expressing Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter Factor Receptor or MET or EC 126.96.36.199) - Drugs in Development, 2021 Summary Cells Expressing Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.